Skip to content
    CLOV
    Earnings call· Jun 2026(Q2 FY26)

    CLOVER HEALTH INVESTMENTS, CORP. /DE Q2 FY26 earnings call CLOV

    Aug 5, 2026 Source

    Executive summary

    Clover Health Q2 FY26 — Strong MA Membership Growth and Profitability

    Clover Health delivered strong Q2 FY26 results, driven by market-leading MA membership growth and improved profitability, with H1 GAAP net income up $67 million. The recalculation to a 4.5-Star rating for PY2027 provides flexibility, but core confidence for 2027 is grounded in continued cohort maturation under Clover Assistant, which is expected to drive further earnings expansion. Management also highlighted new AI initiatives for back-office operations to streamline administrative functions and lower overhead.

    Highlights

    6
    • Medicare Advantage membership grew 48% YoY in H1 2026.

    • GAAP net income increased by $67 million YoY in H1 2026.

    • Total revenue increased by over $550 million YoY to $1.5 billion in H1 2026.

    • Consolidated gross profit increased by $104 million in H1 2026.

    • Operating leverage expanded by over 200 bps in H1 2026.

    • All MA members now enrolled in 4.5 Stars plans for Payment Year 2027.

    Concerns

    3
    • CMS has filed notice of intent to appeal the 4.5-Star rating court decision.

    • Outpatient medical cost trends remain elevated from prior years, though moderated in Q2.

    • Adjusted EBITDA is expected to return to a seasonal loss in Q4 FY26.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full Year 2026 Average Medicare Advantage Membership
    156,000 to 158,000 members
    high materiality
    High
    Full Year 2026 Total Revenue
    $2.92 billion to $3 billion
    high materiality
    High
    Full Year 2026 Consolidated Gross Profit
    $525 million to $555 million
    high materiality
    High
    Full Year 2026 Adjusted EBITDA
    $70 million to $85 million
    high materiality
    High
    Full Year 2026 GAAP Net Income
    $20 million to $35 million
    high materiality
    High
    Q4 FY26 Adjusted EBITDA
    return to a more typical seasonal loss
    medium materiality
    High
    2027 Earnings Potential
    increasing confidence in the earnings potential of the business heading into 2027
    high materiality
    High
    2027 Growth Position
    feel very good about our growth position heading into next year
    high materiality
    High

    Operational metrics

    19
    Medicare Advantage membership growth
    48%YoY
    H1 2026

    Through the first 6 months of the year, we delivered market-leading MA membership growth of 48%

    GAAP net income increase
    $67 millionYoY
    H1 2026

    increasing GAAP net income by $67 million year-over-year

    Total revenue increase
    $550 millionYoY
    H1 2026

    total revenue in the first half increased by more than $550 million year-over-year to $1.5 billion

    Consolidated gross profit increase
    $104 million
    H1 2026

    Consolidated gross profit increased by $104 million

    Operating leverage expansion
    200
    H1 2026

    expanded operating leverage by more than 200 basis points as we've scaled.

    Adjusted EBITDA
    $41 million
    Q2 FY26

    Second quarter adjusted EBITDA totaled $41 million

    GAAP net income
    $28 million
    Q2 FY26

    GAAP net income totaled $28 million

    Average Medicare Advantage membership
    157,000
    Q2 FY26

    Average Medicare Advantage membership increased to 157,000 members during the quarter

    Total revenue
    $743 million56% YoY growth
    Q2 FY26

    driving total revenue of $743 million, an increase of 56% year-over-year.

    Consolidated gross profit
    $153 million54% YoY growth
    Q2 FY26

    Consolidated gross profit totaled $153 million during the quarter, representing 54% year-over-year growth.

    Adjusted SG&A
    $112 million
    Q2 FY26

    Adjusted SG&A totaled $112 million during the quarter

    Adjusted SG&A as % of total revenue
    15%220 bps improvement YoY
    Q2 FY26

    representing 15% of total revenue. That's an improvement of approximately 220 basis points compared to the second quarter of 2025.

    Adjusted EBITDA
    $81 million
    H1 FY26

    Through the first half of the year, we've now generated $81 million of adjusted EBITDA

    GAAP net income
    $55 million
    H1 FY26

    and $55 million of GAAP net income.

    Cash and investments balance
    $443 million
    Q2 FY26

    We ended the quarter with $443 million of cash and investments

    Gross profit improvement PMPM
    $70
    Year 1 to Year 2

    our cohorts typically improve by about $70 PMPM in gross profit as they move from year 1 to year 2.

    Clover Assistant coverage
    low 60slower than 2/3 overall population
    Current

    It's a little bit lower than the 2/3 across our overall population, but you're looking in the low 60s, and then that generally trends up over time.

    2025 cohort percentage of membership
    21%
    Current

    the new member cohort from '25 represents about 21%

    2026 cohort percentage of membership
    28%
    Current

    and then the 2026 cohort is at about 28%.

    Industry KPIs

    8
    MetricValueDetails
    Utilization trendsfavorable overall
    Stars rate environment4.5 Stars
    Medical loss care ratio
    Client retention new winshigh
    Pharmacy scripts specialty
    Membership covered lives by line157,000members
    Adjusted EPS EBITDA leverage guidanceAdjusted EBITDA: $70M-$85M; GAAP Net Income: $20M-$35MUSD
    Medical cost trend vs pricing assumptionperforming better than expected

    Risks & headwinds

    3
    CMS appeal of 4.5-Star rating court decisionongoing

    pending litigation

    Mitigation: prepared to defend it on appeal; remain focused on bringing affordable, high-quality care to seniors on Medicare in our 4.5-Star plans.

    Elevated outpatient medical cost trendsQ2 FY26

    remain elevated from prior years

    Mitigation: within our expectations, and we continue to monitor closely.

    Seasonal loss in Adjusted EBITDAQ4 FY26

    return to a more typical seasonal loss

    Mitigation: expected quarterly shape is consistent with how we plan the business; investments to increase during the fourth quarter, including AEP-related activities.

    What to watch in Q3 FY26

    4

    CMS appeal outcome for 4.5-Star rating

    Ongoing
    CurrentCMS has filed notice of intent to appeal the District Court's decision.
    TargetResolution of the appeal, confirmation of 4.5-Star rating for PY2027.

    Why it matters

    The 4.5-Star rating provides flexibility for product offerings, growth, and profitability for PY2027.

    CMS has filed notice of its intent to appeal the District Court's decision. Because this regards pending litigation, I'll be brief, we believe the District Court's ruling was thorough and well reasoned, and we are prepared to defend it on appeal.

    Q&A highlights

    7

    What percentage of members in the 2025 and 2026 cohorts are managed under Clover Assistant, especially given the focus on New Jersey and Georgia?

    Clover Assistant coverage for the 2025 and 2026 cohorts is in the low 60s, which is slightly lower than the overall population average but generally trends up over time as members stay longer with Clover.

    It's a little bit lower than the 2/3 across our overall population, but you're looking in the low 60s, and then that generally trends up over time.

    asked by Richard Close · answered by Clay Thornton

    2 min read6 chapters

    Detailed Narrative

    01

    AI-Powered Care Model and Clover Assistant

    Clover Health emphasizes its AI-powered model, Clover Assistant, as a core differentiator. The technology helps physicians make better decisions, leading to improved clinical care, membership growth, and increased profitability. This approach has contributed to Clover becoming the top-rated HEDIS PPO plan in the country, and the company is extending this model through Counterpart Health, recognizing the broader industry's potential for technology built around clinical decisions.

    02

    Impact of 4.5-Star Rating for 2027

    Following a court order and CMS recalculation, all Medicare Advantage members are now enrolled in plans rated 4.5 Stars for payment year 2027. While CMS intends to appeal, the company is confident in the ruling and believes the higher rating provides flexibility to reinvest in members, maintain a competitive product, support growth, and expand profitability. However, management clarifies that the rating provides flexibility in value allocation, but Clover Assistant is what creates the value.

    03

    Cohort Maturation as Key Earnings Driver

    The primary driver of confidence for 2027 and beyond is the continued maturation of member cohorts under Clover Assistant. New members initially create near-term pressure📎, but their economics improve over time as they engage with the platform. The company expects cohorts to improve by approximately $70 PMPM in gross profit from year 1 to year 2, with further step-ups in year 3, leading to increasing confidence in the business's earnings potential.

    04

    Strong First Half 2026 Performance

    The first half of 2026 demonstrated strong performance with market-leading MA membership growth of 48% and a $67 million year-over-year increase in GAAP net income. Total revenue grew by over $550 million to $1.5 billion, and consolidated gross profit increased by $104 million. Operating leverage expanded by over 200 basis points, validating the AI-powered model's ability to improve care and strengthen the business.

    05

    Medical Cost Trends and SG&A Efficiency

    Medical cost trends are performing better than expected, particularly inpatient utilization, which is tracking below prior year's new member cohort. Outpatient trends moderated in Q2 after peaking in March, remaining within expectations. Adjusted SG&A totaled $112 million in Q2, representing 15% of total revenue, an improvement of 220 basis points YoY, demonstrating operating leverage as the company scales.

    06

    Future AI Integration in Operations

    Beyond clinical applications, Clover Health plans to integrate AI into its back-office insurance operations to improve claims processing speed and accuracy, and to streamline administrative functions. This initiative is expected to further lower overhead and compound margin opportunities over time, driving both clinical and operational efficiency and positioning the business well for the years ahead.

    AI-generated summary of the company’s earnings call. Not investment advice.